Upcoming FDA Guidance Will Offer New Thinking On Drug-Eluting Stents
This article was originally published in The Pink Sheet Daily
Executive Summary
Document will address premarket and postmarket recommendations for heavily scrutinized products.
You may also be interested in...
Study Shows No Death, MI Advantages For Stenting Over Medical Therapy
Results form the 2,287-patient COURAGE trial presented the American College of Cardiology meeting should give physicians more to think about before moving forward with percutaneous coronary intervention in stable heart disease patients, researchers say.
FDA Aims To Up Transparency By Making Panel Materials Public Sooner
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week
New England Journal of Medicine Documents Drug-Eluting Stent Debate
FDA argues for larger and longer studies in article.